Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: DIASTAT

« Back to Dashboard
Diastat is a drug marketed by Valeant Pharms North and is included in one NDA. It is available from two suppliers.

The generic ingredient in DIASTAT is diazepam. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the diazepam profile page.

Summary for Tradename: DIASTAT

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list6

Pharmacology for Tradename: DIASTAT

Ingredient-typeBenzodiazepines
Drug ClassBenzodiazepine

Clinical Trials for: DIASTAT

Comparison of Absorption of Vaginal Diazepam Using Different Delivery Systems
Status: Terminated Condition: Metabolism, Drug

A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Status: Completed Condition: Epilepsy

A Study to Determine the Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)
Status: Recruiting Condition: Refractory Epilepsy

A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers
Status: Recruiting Condition: Healthy

Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
Status: Completed Condition: Seizures

Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam
Status: Active, not recruiting Condition: Posttraumatic Stress Disorder

Freedom SOLO Stentless Heart Valve Study
Status: Completed Condition: Aortic Stenosis; Aortic Insufficiency

Exploring the Effects of Diazepam and Lorazepam
Status: Completed Condition: Healthy Subjects

Vaginal Diazepam for the Treatment of Female Pelvic Pain
Status: Recruiting Condition: Pelvic Floor Disorders; Pelvic Pain

A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal
Status: Completed Condition: Alcohol Withdrawal

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North
DIASTAT
diazepam
GEL;RECTAL020648-001Jul 29, 1997RXNo<disabled><disabled>
Valeant Pharms North
DIASTAT ACUDIAL
diazepam
GEL;RECTAL020648-006Sep 15, 2005RXYes<disabled><disabled>
Valeant Pharms North
DIASTAT
diazepam
GEL;RECTAL020648-004Jul 29, 1997DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DIASTAT

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North
DIASTAT
diazepam
GEL;RECTAL020648-001Jul 29, 19975,462,740<disabled>
Valeant Pharms North
DIASTAT
diazepam
GEL;RECTAL020648-005Jul 29, 19975,462,740<disabled>
Valeant Pharms North
DIASTAT
diazepam
GEL;RECTAL020648-002Jul 29, 19975,462,740<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DIASTAT

Drugname Dosage Strength RLD Submissiondate
diazepamRectal Gel5 mg/mL, 2mL pre-filled syringeDiastat Acudial12/23/2008
diazepamRectal Gel5 mg/mL, 4mL pre-filled syringeDiastat Acudial12/8/2008
diazepamRectal Gel2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mLDiastat3/23/2004
« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc